Prof. Chongbiao Huang 黄崇标
Chief Physician, Professor
Department of Lung Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Lung cancer surgery, including thoracoscopic lobectomy, segmentectomy, lymph node dissection, and single-port thoracoscopy. Focuses on function preservation, enhanced recovery after surgery, and personalized comprehensive treatment.
Dr. Huang holds a medical doctorate and serves as Chief Physician, Professor, and doctoral supervisor at Tianjin Medical University Cancer Institute & Hospital. Recognized as a national-level young talent and Tianjin Outstanding Youth, Dr. Huang leads research in lung cancer diagnosis and treatment, emphasizing precise, minimally invasive surgery and standardized, personalized comprehensive care.
Name order: in Chinese the family name comes first (Huang Chongbiao). Papers usually list the name as Chongbiao Huang or Huang C.
Selected publications
68 papers on PubMed matched by name and affiliation; 14 as first or senior author since 2016. Most recent first- or senior-author papers:
- Signal Transduct Target Ther, 2026 (first author): Retraction Note: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. PubMed 41484065
- Ecotoxicol Environ Saf, 2026 (senior author): Molecular mechanisms and clinical insights of benzo[a]pyrene-related lung adenocarcinoma: New discoveries in multi-scale approaches. PubMed 41601038
- Adv Sci (Weinh), 2026 (senior author): Tumor-Derived Interleukin 35 Promotes Fibrosis in the Tumor Microenvironment of Pancreatic Cancer by Activating Pancreatic Stellate Cells. PubMed 41235536
- Am J Transl Res, 2024 (senior author): Clinical effect of Almonertinib in treating epidermal growth factor receptor mutation-positive residual ground-glass opacities after stage I lung cancer resection. PubMed 39822544
- Oncogene, 2024 (senior author): Tumor-derived interleukin 35 mediates the dissemination of gemcitabine resistance in pancreatic adenocarcinoma. PubMed 38243080
- Signal Transduct Target Ther, 2024 (first author): Correction: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. PubMed 38177109
- Signal Transduct Target Ther, 2023 (first author): BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. PubMed 37443111
- Front Oncol, 2022 (senior author): MIF promotes cell invasion by the LRP1-uPAR interaction in pancreatic cancer cells. PubMed 36703790
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion